Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?

INTRODUCTION: Monoclonal antibodies targeting interleukin 5 (IL5) or its receptor (IL5R) are frequently used in severe asthma, in which they reduce exacerbations rate and oral corticosteroids (OCS) exposure. Anti-IL5/IL5Rs have been studied in patients with chronic obstructive pulmonary disease (COP...

Descripción completa

Detalles Bibliográficos
Autores principales: Laroche, Jérémy, Pelletier, Geneviève, Boulay, Marie-Ève, Côté, Andréanne, Godbout, Krystelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167963/
https://www.ncbi.nlm.nih.gov/pubmed/37180748
http://dx.doi.org/10.2147/COPD.S370165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167963/
https://www.ncbi.nlm.nih.gov/pubmed/37180748
http://dx.doi.org/10.2147/COPD.S370165

Ejemplares similares